Clinical and molecular features of small cell lung cancer

Cancer Biology and Therapy

Volumn 1, Issue 2, 2002, Pages 105-112

  Campbell, Allyson M ^a   Campling, Barbara G ^a   Algazy, Kenneth M ^a   El Deiry, Wafik S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Genetic alteration; Neuroendocrine tumor; Oncogene; Paraneoplastic syndrome; Prognostic indicators; Signal transduction; Small cell lung cancer; Tumor suppressor gene

Indexed keywords

GASTRIN RELEASING PEPTIDE; STEM CELL FACTOR;

AGED; ARTICLE; CASE REPORT; DNA METHYLATION; GENETICS; HUMAN; LUNG TUMOR; MALE; ONCOGENE; PARANEOPLASTIC SYNDROME; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SMALL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

AGED; CARCINOMA, SMALL CELL; DNA METHYLATION; GASTRIN-RELEASING PEPTIDE; GENES, P53; HUMANS; LUNG NEOPLASMS; MALE; ONCOGENES; PARANEOPLASTIC SYNDROMES; PROGNOSIS; STEM CELL FACTOR;

EID: 0036490420     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.52     Document Type: Article

References (71)

1. Sekido Y, Fong KM, Minna JD. Molecular biology of lung cancer. In: DeVita VT, 2. Hellman S, Rosenberg SA, eds. Cancer: Principals and practice of oncology, Philadelphia, Lippincott Williams and Wilkins, 2001; pp.917-25.
2. Murren J, Glatstin E, Pass HI. Small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principals and practice of oncology, Philadelphia, Lippincott Williams and Wilkins, 2001; pp.983-1018.
3. Campling B, Quirt I, DeBoer G, Feld R, Shepard FA, Evans WK. Is bone marrow examination in small-cell lung cancer really necessary? Ann Intern Med 1986; 105:508-512.
4. Arnold SM, Patchell R, Lowy AM, Foon KA. Paraneoplastic syndromes. In: DeVita VT, Hellman S, and Rosenberg SA, eds. Cancer: Principals and practice of oncology, Philadelphia, Lippincott Williams and Wilkins, 2001; pp.2511-36.
5. Musunuru K, Darnell RB. Paraneoplastic Neurologic Disease Antigens: RNA-binding proteins and signaling proteins in neuronal degeneration. Annu Rev Neurosci 2001; 24:239-62. (Pubitemid 32695229)
6. Rees J. Paraneoplastic syndromes. Current Opin Neurol 1998; 6:633-7. (Pubitemid 28561197)
7. Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with cerebellar degeneration. Ann Neurol 2000; 47:9-17. (Pubitemid 30033645)
8. Lee JS, Mao L, Hong WK. Biology of preneoplastic lesions. In: Roth JA, Cox JD, Hong WK, eds. Lung Cancer, 2nd Edition. Malden, MA: Blackwell Science, Inc., 1998; 45-6.
9. Junker K, Weithege TH, Muller KM. Pathology of small-cell lung cancer. J Cancer Res Clin Oncol 2000; 126:361-8. (Pubitemid 30436371)
10. Kurose K, Hoshaw-Woodard S, Adeyinka A, Lemeshow S, Watson PH, Eng C. Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumor-microenvironment interactions. Hum Mol Genet 2001; 10:1907-13. (Pubitemid 32910535)
11. Chute JP, Venzon DJ, Hankins L, et al. Outcome of patients with small cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc 1997; 72:901.
12. Turrisi AT, Kim K, Blum R, Sause W, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265-71. (Pubitemid 29063268)
13. Auperin A, Arriagada R, Pignon J-P, Le Pechoux C, Gregor A, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341:476-84. (Pubitemid 29372887)
14. Das A, Hochberg FH, McNelis S. A review of the therapy of paraneoplastic neurologic syndromes. J Neurooncol 1999; 41:181-94. (Pubitemid 29161014)
15. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999; 17:1794-1801. (Pubitemid 29269249)
16. Masuda N, Matsui K, Negoro S, Takefuji N, Takeda K, Yana T, et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1998; 16:3329-34. (Pubitemid 28481629)
17. The National Cancer Institute (NCI) website CancerNet: http://cancernet.nci.nih.gov;
18. University of Pennsylvania cancer resource: www.oncolink.com;
19. Southwest Oncology Group Clinical Trials: www.swog.org;
20. UKCCCR Clinical Trials Registry, a database of British randomized clinical trials: www.cto.mrc.ac.uk/ukcccr/;
21. Coalition of National Cancer Cooperative Groups, Inc.: www.ca-coalition.org/index.html
22. Young LC, Campling BG, Voskoglou-Nomikos T, Cole SP, Deeley RG, Gerlach JH. Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res 1999; 5:673-80. (Pubitemid 29131979)
23. Mirski SE, Sparks KE, Yu Q, Lang AJ, Jain N, Campling BG, et al. A truncated cytoplasmic topoisomerase II alpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34. Int J Cancer 2000; 85:534-9. (Pubitemid 30075133)
24. Giaccone G, Gazdar AF, Beck H, Zunino F, Capraninco G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 1992; 52:1666-74.
25. Sekido Y, Fong K, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1378 1998; F21-F59. (Pubitemid 28381125)
26. Kohno T, Yukota J. How many tumor suppressor genes are involved in human lung carcinogenesis? Carcinogenesis 1999; 20:1403-10.
27. Bunn PA, Soriano A, Johnson G, Heasley L. New therapeutic strategies for lung cancer: biology and molecular biology come of age. Chest 2000; 117(4 suppl 1):163S-8S.
28. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001; 28(2 suppl 4):3-13. (Pubitemid 32730372)
29. Pass HI, Kalemkerian G, Bright RK. Novel molecular and immunotherapeutic strategies for lung cancer. Chest Surg Clin of North Amer 2001; 11:189-213.
30. Chen JJW, Peck K, Hong TM, Yang SC, et al. Global analysis of gene expression in invasion by a lung cancer model. Cancer Res 2001; 61:5223-30. (Pubitemid 32681557)
31. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelo-typing of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer and loci clustering. Cancer Res 2000; 60:4894-906.
32. Lindblad-Toh K, Tanenbaum DM, Daly MJ, Winchester E, Liu WO, et al. Loss-of-heterozygosity analysis of small cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol 2000; 118:1001-05. (Pubitemid 32977384)
33. Grandori C, Eisenman RN. Myc target genes. Trends Biochem Sci 1997; 22:177-81. (Pubitemid 27199319)
34. Krystal G, Birrer M, Way J, Nau M, et al. Multiple mechanisms for transcriptional regulation of the myc gene family in small cell lung cancer. Mol Cell Biol 1988; 8:3373-81.
35. Johnson BE, Russell E, Simmons AM, et al. Myc family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. J Cell Biochem 1996; 24:210-7.
36. Dosaka-Akita H, Akie K, Hiroumi H, et al. Inhibition of proliferation of L-myc antisense DNA for the translation initiation site in human small cell lung cancer. Cancer Res 1995; 55:1559-64.
37. Kumagai T, Tanio Y, Osaki T, et al. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements. Cancer Res 1996; 56:354-8. (Pubitemid 26026365)
38. Viallet J, Sausville EA. Involvement of signal transduction pathways in lung cancer biology. J Cell Biochem 1996; 24:228-36.
39. King KA, Hua J, Torday JS, et al. CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides. J Clin Invest 1993; 91:1969.
40. Halmos G, Schally AV. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small cell lung cancer after treatment with bombesin antagonist RC-3095. Proc Natl Acad Sci USA 1997; 94:956-60. (Pubitemid 27074429)
41. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996; 56:370-6.
42. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-6. (Pubitemid 32267975)
43. Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI-571 inhibits small cell lung cancer growth. Clinical Cancer Res 2000; 6:3319-26. (Pubitemid 30637763)
44. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer lines by the novel tyrosine kinase inhibitor STI-571. Oncogene 2000; 19:3521-8. (Pubitemid 30487449)
45. Krystal GW, Honsawek S, Kiewlich D, Liang CX, Vasile S, et al. Indolinone tyrosine kinase inhibitors block kit activation and growth of small cell lung cancer cells. Cancer Res 2001; 61:3660-8. (Pubitemid 32694977)
46. Harris CC. p53 tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis 1996;17:1187-98.
47. Hollstein M, Shomer B, Greenblatt M, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucl Acid Res 1996; 24:141.
48. Denissenko MF, Pai A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 1996; 274:430-2. (Pubitemid 26353359)
49. Smith, LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M, et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 2000; 92:803-11. (Pubitemid 30368036)
50. Takahashi T, Carbone D, Nau MM, HildaT, Linnoila I, Ueda R, et al. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 1992; 52:2340-43.
51. Tanaka H, Fujii Y, Hirabayahi H, et al. Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. Int J Cancer 1998;79:111-5. (Pubitemid 28201679)
52. Cagle PT, El-Naggar AK, Xu HJ, Hu SX, Benedict WF. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung: potential diagnostic implications. Am J Pathol 1997; 150:393-400. (Pubitemid 27073768)
53. Gazzeri S, Gouyer V. Inactivation of RB gene and pRB function in lung cancer. In Lung Tumors: fundamental biology and clinical management. Brambilla C, Brambilla E, eds. New York: Marcel Dekker, 1999:198-9.
54. Okawa K, Shiseki K, Takahashi R, Yoshida Y, Terada M. Reconstitution of the RB gene suppresses the growth of small cell lung carcinoma cells carrying multiple genetic alterations. Oncogene 1993; 8:2175-82.
55. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumor-type specific patterns. Nat Genet 2000; 24:132-8.
56. Virmani AK, Rahti A, Zochbauer-Muller S, et al. Promoter methylation and silencing of the retinoic acid receptor beta gene in lung carcinomas. J Natl Cancer Inst 2000;92:1303-7. (Pubitemid 30660589)
57. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nat Genet 2000;25:315-9. (Pubitemid 30437320)
58. Burbee D, Forgacs E, Zochbauer-Muller S, et al. RASFF1A in the 3p21.3 homozygous deletion region: epigenetic inactivation in lung and breast cancer and suppression of the malignant phenotype. J Natl Cancer Inst 2001; 93:691-9. (Pubitemid 32492810)
59. Adjei AA, Marks RS, Bonner JA. Current guidelines for the management of small cell lung cancer. Mayo Clin Proc 1999; 74:809-16. (Pubitemid 29362588)
60. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000; 89:523-33. (Pubitemid 30640099)
61. Collichio FA, Woolf PD, Brower M. Management of patients with small cell carcinoma and the syndrome of ectopic corticotropin secretion. Cancer 1994; 73:1361-7. (Pubitemid 24072540)
62. Posner JB, Dalmau JO. Paraneoplastic syndromes affecting the central nervous system. Annu Rev Med 1997; 48:157-66. (Pubitemid 27101821)
63. Graus F, Dalmau J, Rene R, Tora M, Malats N, Verschuuren JJ, et al. Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival. J Clin Oncol, 1997; 15:2866-72. (Pubitemid 27330014)
64. Tritz DB, Doll DC, Ringenberg QS, Anderson S, Madsen R, Perry MC, et al. Bone marrow involvement in small cell lung cancer: clinical significance and correlation with routine laboratory values. Cancer 1989; 63:763-6. (Pubitemid 19050282)
65. Johnson DH, de Leo M, Greco FA. Bone marrow examination in small cell lung cancer (Letter). Ann Intern Med 1987; 106;170-1.
66. Rodriguez-Salas N, Palacios J, de Castro J, Moreno G, Gonzalez-Baron M, Gamallo C. Beta-catenin expression pattern in small cell lung cancer: correlation with clinical and evolutive features. Histol Histopathol 2001; 16:353-8. (Pubitemid 32297632)
67. Micke P, Hengstler JG, Ros R, Bittinger F, Metz T, et al. c-erbB-2 expression in small cell lung cancer is associated with poor prognosis. Int J Cancer 2001; 92:474-9. (Pubitemid 32319418)
68. Fischer JR, Schindel M, Bulzebruck H, Lahm H, Krammer PH, Drings P. Long-term survival in small cell lung cancer patients is correlated with high interluekin-2 secretion at diagnosis. J Cancer Res Clin Oncol 2000; 126:730-3.
69. Daly MC, Douglas JB, Bleehan NM, Hastleton P, Twentyman PR, et al. An unusually proximal deletion on the short arm of chromosome 3 in a patient with small cell lung cancer. Genomics 1991; 9:113-9.
70. Hibi K, Takahashi T, Yamakawa K, et al. Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 1992; 7:445-9.
71. Killary AM, Wolf ME, Giambernardi TA, Naylor SL. Definition of a new tumor suppressor locus within human chromosome 3p21-p22. Proc Natl Acad Sci USA 1992; 89:10877-81.